ADG206-1001
03 Jan 2023
Trial Summary
ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.
Acronym:
ADG206-1001
ACTRN/NCT /ethics:
NCT05614258
Scientific title:
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Sponsor / Cooperative group:
Adagene Inc
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2022-12-01 |
| Anticipated End Date | 2024-12-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Carolyn Bampton |
| Recruitment Status | Recruiting |